[1] 奈玛特韦片/利托那韦片组合包装说明书, 国药准字 HJ20220006. 核准日期:2022 年 02 月 11 日 [Z].[2] 国家卫生健康委办公厅, 国家中医药局综合司.《新型冠状病毒感染诊疗方案试行第十版）》[EB/OL].(2023-01-05)/[2023-01-07]./ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml[3] World Health Organization. Therapeutics and Covid-19: Living Guideline [EB/OL]. (2022-09-16)/[2022-12-02].[4] National Institutes Of Health. Coronavirus Disease 2019 (Covid-19) Treatment Gu ideliness [EB/OL]. (2022-12-01)/[2022-12-02].[5] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2022 Sep 5:ciac724.[6] COVID-19 Supplemental Clinical Guidance #4: Nirmatrelvir/Ritonavir (Paxlovid) Use in Patients With Advanced Chronic Kidney Disease and Patients on Dialysis with COVID-19. Ontario renal network, April 13, 2022[7] 日本厚生省. 新型冠状病毒肺炎治疗手册第 8.1 版 [M].2022.10：10-15[8] DRUGs,/dosage/paxlovid.html[9] 广东省药学会.《广东省心血管患者使用奈玛特韦/利托那韦片（Paxlovid）临床药学指引》. /download/172.html[10] 张福杰, 王卓, 王全红, 等. 新型冠状病毒感染者抗病毒治疗专家共识 [J]. 中华临床感染病杂志,2023,16(1):10-20.[11] 浙江省医院药事管理质控中.《浙江省新型冠状病毒感染临床用药建议》./ZXDT/ShowContent_11817.htm[12] 北京协和医院新型冠状病毒感染基层诊疗建议多学科专家组. 北京协和医院新型冠状病毒感染基层诊疗建议 (2023)[J]. 协和医学杂志,2023,14(1):60-74.[13] 湘雅医院, 中南大学湘雅医院新型冠状病毒诊疗方案（试行）.[14]Protocol for: Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High Risk, Nonhospitalized Adults with COVID-19. N Engl J Med. 2022; 386(15):1397-1408.[15]Toussi S, Neutel J, Navarro J, et al. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment. Clin Pharmacol Ther. 2022;112(4):892-900.[16]Hiremath S, McGuinty M, Argyropoulos C, et al. Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD. Clin J Am Soc Nephrol 2022;17(8):1247-50.[17] Hiremath S, Blake PG, Yeung A, et al. Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients withCoronavirusDisease 2019. Clin J Am Soc Nephrol. 2023;18(4):485-490.[18] Lingscheid T, Kinzig M, Krüger A, et al. Pharmacokinetics of Nirmatrelvir and Ritonavir in Covid-19 Patients with End-Stage Renal Disease on Intermittent Hemodial ysis [J]. Antimicrob Agents Chemother, 2022, 66(11): e0122922.
(资料图片仅供参考)
